Abstract
A 49-year-old man with pulmonary metastasis from renal cell carcinoma (RCC) was treated with recombinant IFN-α2b (Intron A®). A complete response was achieved within 4 months and thereafter persisted for 5 years until he developed another lung lesion. Interleukin-2 (Imunace®) was administered without any response. Finally, lie was treated by natural IFN-α (OIF®). The pulmonary lesion achieved a partial response after 11 months of treatment. Because IFN-α preparations include different subtypes, changing the use of IFN-α preparations may thus be a potentially useful option for the successful immunotherapy of RCC.
| Original language | English |
|---|---|
| Pages (from-to) | 135-137 |
| Number of pages | 3 |
| Journal | Biomedical Research |
| Volume | 26 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2005 Jun |
Fingerprint
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
Cite this
Repeated regression of pulmonary metastases from renal cell carcinoma after treatment using different interferon-alpha preparations. / Oya, Mototsugu; Asakura, Hirotaka; Mizuno, Ryuichi; Marumo, Ken; Murai, Masaru.
In: Biomedical Research, Vol. 26, No. 3, 06.2005, p. 135-137.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Repeated regression of pulmonary metastases from renal cell carcinoma after treatment using different interferon-alpha preparations
AU - Oya, Mototsugu
AU - Asakura, Hirotaka
AU - Mizuno, Ryuichi
AU - Marumo, Ken
AU - Murai, Masaru
PY - 2005/6
Y1 - 2005/6
N2 - A 49-year-old man with pulmonary metastasis from renal cell carcinoma (RCC) was treated with recombinant IFN-α2b (Intron A®). A complete response was achieved within 4 months and thereafter persisted for 5 years until he developed another lung lesion. Interleukin-2 (Imunace®) was administered without any response. Finally, lie was treated by natural IFN-α (OIF®). The pulmonary lesion achieved a partial response after 11 months of treatment. Because IFN-α preparations include different subtypes, changing the use of IFN-α preparations may thus be a potentially useful option for the successful immunotherapy of RCC.
AB - A 49-year-old man with pulmonary metastasis from renal cell carcinoma (RCC) was treated with recombinant IFN-α2b (Intron A®). A complete response was achieved within 4 months and thereafter persisted for 5 years until he developed another lung lesion. Interleukin-2 (Imunace®) was administered without any response. Finally, lie was treated by natural IFN-α (OIF®). The pulmonary lesion achieved a partial response after 11 months of treatment. Because IFN-α preparations include different subtypes, changing the use of IFN-α preparations may thus be a potentially useful option for the successful immunotherapy of RCC.
UR - http://www.scopus.com/inward/record.url?scp=27244461045&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27244461045&partnerID=8YFLogxK
U2 - 10.2220/biomedres.26.135
DO - 10.2220/biomedres.26.135
M3 - Article
VL - 26
SP - 135
EP - 137
JO - Biomedical Research (Japan)
JF - Biomedical Research (Japan)
SN - 0388-6107
IS - 3
ER -